1921
Volume 103, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

There is no abstract available for this article.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.20-0569
2020-09-02
2020-09-28
Loading full text...

Full text loading...

/deliver/fulltext/14761645/103/3/tpmd200569.html?itemId=/content/journals/10.4269/ajtmh.20-0569&mimeType=html&fmt=ahah

References

  1. Herrick JA, Bustos JA, Clapham P, Garcia HH, Loeb JA, for the Cysticercosis Working Group in Peru, 2020. Unique characteristics of epilepsy development in neurocysticercosis. Am J Trop Med Hyg 103: 639645.
    [Google Scholar]
  2. World Health Organization, 2014. Assembling a framework for intensified control of taeniasis and neurocysticercosis caused by Taenia solium. Report of an Informal Consultation. Geneva, Switzerland: WHO Headquarters. Available at: https://www.who.int/neglected_diseases/resources/9789241508452/en/. Accessed June 12, 2020.
    [Google Scholar]
  3. World Health Organization, 2019. Epilepsy: A Public Health Imperative. Geneva, Switzerland: WHO. License: CC BY-NC-SA 3.0 IGO.
    [Google Scholar]
  4. White AC Jr., Coyle CM, Rajshekhar V, Singh G, Hauser WA, Mohanty A, Garcia HH, Nash TE, 2018. Diagnosis and treatment of neurocysticercosis: 2017 clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Am J Trop Med Hyg 98: 945966.
    [Google Scholar]
  5. Thurman DJ, Begley CE, Carpio A, Helmers S, Hesdorffer DC, Mu J, Touré K, Parko KL, Newton CR, 2018. The primary prevention of epilepsy: a report of the prevention task force of the international league against epilepsy. Epilepsia 59: 905914.
    [Google Scholar]
  6. Beghi E, Carpio A, Forsgren L, Hesdorffer DC, Malmgren K, Sander JW, Tomson T, Hauser WA, 2010. Recommendation for a definition of acute symptomatic seizure. Epilepsia 51: 671675.
    [Google Scholar]
  7. Carpio A, Escobar A, Hauser WA, 1998. Cysticercosis and epilepsy: a critical review. Epilepsia 39: 10251040.
    [Google Scholar]
  8. Tellez-Zenteno JF, Hernandez-Ronquillo L, 2017. Epidemiology of neurocysticercosis and epilepsy, is everything described? Epilepsy Behav 76: 146150.
    [Google Scholar]
  9. Abba K, Ramaratnam S, Ranganathan LN, 2010. Anthelmintics for people with neurocysticercosis. Cochrane Database Syst Rev 2010: CD000215.
    [Google Scholar]
  10. Singh G, Sharma R, 2017. Controversies in the treatment of seizures associated with neurocysticercosis. Epilepsy Behav 76: 163167.
    [Google Scholar]
  11. Carpio A, Chang M, Zhang H, Romo ML, Jaramillo A, Hauser WA, Kelvin EA, 2019. Exploring the complex associations over time among albendazole treatment, cyst evolution, and seizure outcomes in neurocysticercosis. Epilepsia 60: 18201828.
    [Google Scholar]
  12. Carpio A, Romo ML, 2015. Multifactorial basis of epilepsy in patients with neurocysticercosis. Epilepsia 56: 973974.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.20-0569
Loading
  • Received : 29 May 2020
  • Accepted : 17 Jun 2020
  • Published online : 02 Sep 2020
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error